Synthesis and Activity of a Novel Series of 3-Biarylquinuclidine Squalene Synthase Inhibitors
作者:George R. Brown、David S. Clarke、Alan J. Foubister、Susan Freeman、Peter J. Harrison、Michael C. Johnson、Keith B. Mallion、John McCormick、Fergus McTaggart、Alan C. Reid、Graham J. Smith、Melvyn J. Taylor
DOI:10.1021/jm950907l
日期:1996.1.1
Quinuclidines with a 3-biaryl substituent are a new class of potent, orally active squalene synthase (SQS) inhibitors. Variants around these rigid structures indicate key structural requirements for cationic SQS inhibitors. Thus the lower in vitro potency found for quinuclidines bearing 3-substituents, which did not overlay the biphenyl group of 3-(biphenyl-4-yl)-3-hydroxyquinuclidine (2) (IC50 = 16
具有3-联芳基取代基的喹核苷是一类新的有效的,口服活性的角鲨烯合酶(SQS)抑制剂。这些刚性结构周围的变化指示出阳离子SQS抑制剂的关键结构要求。因此,暗示了带有3个取代基的喹核苷的体外效价较低,该奎尼啶没有覆盖3-(联苯基-4-基)-3-羟基喹核苷(2)的联苯基团(IC50 = 16 nM,大鼠微粒体SQS)。 3取代基的方向性要求。类似地,3-三联苯类似物6的较低效能(IC50 = 370 nM)表明该取代基的尺寸受到限制。在具有奎宁环和联苯环之间连接基团的化合物中,亲脂性较低的连接基团的耐受性较差(例如,17,CH2CH2,IC50 = 5 nM与19,NHCO,IC50 = 1.2 microM)。用更具极性的吡啶杂环取代2的远端苯环会导致体外效能降低。通常,大鼠体内的良好体内活性仅限于3-羟基类似物,其中3- [4-(吡啶-4-基)苯基]衍生物39(IC50 = 161 nM)显示出最佳的抑制作用(口服给药后)